Lucentis0.5 mg/0.05 ml

Lucentis is a vascular endothelial growth factor (VEGF) inhibitor administered by intravitreal injection. Its indications, classified by strength of evidence, are:

Established / approved indications

• Neovascular (wet) age-related macular degeneration (AMD): to reduce abnormal choroidal neovascularization and vision loss.
• Diabetic macular edema (DME): to reduce macular thickening and improve visual acuity.
• Diabetic retinopathy (DR), including in patients with DME: to reduce progression of retinopathy.
• Macular edema following retinal vein occlusion (RVO) (branch or central RVO): to reduce edema and improve vision.
• Myopic choroidal neovascularization (myopic CNV): typically as a short course of monthly injections.
• Retinopathy of prematurity (ROP) in preterm infants, using a lower pediatric-specific dose, under specialist ophthalmology supervision.

Lucentis is used only for these retinal/ocular vascular conditions; it has no approved systemic (oral/IV) indication.

Each single-use vial/pre-filled syringe of Ranibizumab contains Ranibizumab (recombinant humanized anti-VEGF monoclonal antibody fragment) as a sterile, preservative-free aqueous solution for intravitreal injection, typically supplied as 10 mg/mL strength (delivering a 0.5 mg or 0.3 mg dose, or a lower pediatric dose for ROP, depending on formulation), along with pharmaceutical excipients (e.g. histidine, trehalose, polysorbate 20, water for injection) to maintain stability and pH.

Lucentis is a recombinant humanized monoclonal antibody fragment (Fab fragment) that binds to and inhibits vascular endothelial growth factor A (VEGF-A), a protein that drives abnormal blood vessel growth (angiogenesis) and vascular leakage in the retina and choroid.

By neutralizing VEGF-A, Lucentis reduces neovascularization and vascular permeability, which helps limit fluid accumulation, retinal thickening, and progressive vision loss in several retinal vascular diseases. It is administered only as an intravitreal injection directly into the eye by a qualified ophthalmologist under sterile conditions; it is not given orally or systemically.

Lucentis belongs to the therapeutic class of anti-VEGF (vascular endothelial growth factor) agents / ophthalmic anti-angiogenic biologics, used in the management of neovascular and edematous retinal diseases.

Mechanism of action

Ranibizumab is a Fab fragment of a humanized monoclonal antibody that binds with high affinity to all biologically active isoforms of VEGF-A (including VEGF110, VEGF121, and VEGF165). By binding VEGF-A, Ranibizumab prevents its interaction with the VEGF receptors VEGFR-1 and VEGFR-2 on vascular endothelial cells, thereby suppressing endothelial cell proliferation, neovascularization, and vascular leakage.

Pharmacokinetics

After intravitreal injection, Ranibizumab is absorbed slowly into the systemic circulation, where serum concentrations are very low compared with intraocular concentrations. Vitreous half-life is approximately 9 days; systemic clearance is rapid once absorbed, and systemic VEGF suppression is minimal at approved doses. Elimination is thought to occur via proteolytic degradation, similar to other antibody fragments.

Lucentis is for intravitreal injection only, performed exclusively by a qualified ophthalmologist. Administration involves:

• Adequate anesthesia and periocular antisepsis (e.g. povidone-iodine) of the eyelid, eyebrow, and ocular surface.
• Use of a sterile field, sterile gloves, and a sterile lid speculum.
• Slow injection of the drug into the vitreous cavity using proper aseptic technique, avoiding the horizontal meridian.
• Monitoring of intraocular pressure and optic nerve head perfusion immediately after injection.
• Instructing the patient to report any eye pain, redness, photophobia, blurred or decreased vision, or floaters immediately after the procedure.

Lucentis must never be self-administered or injected by anyone other than a trained ophthalmic professional.

Because Lucentis is administered locally into the eye with minimal systemic absorption, clinically significant systemic drug-drug interactions are not well established. Points of clinical relevance include:

• Other intravitreal anti-VEGF agents: concurrent use of another anti-VEGF agent in the same eye is not recommended due to lack of safety/efficacy data and potential additive ocular risk.
• Systemic anti-angiogenic or antiplatelet/anticoagulant therapy: patients on these agents may theoretically have altered bleeding risk at the injection site; caution and physician judgment are advised, though robust interaction data are limited.
• Ocular procedures/medications: other intraocular or periocular procedures performed close in time to Lucentis injection may increase the risk of infection or intraocular pressure elevation; spacing of procedures should be individualized by the ophthalmologist.

Side effects of Lucentis may relate either to the intravitreal injection procedure itself or to the drug's pharmacological effect.

Common

• Conjunctival hemorrhage, eye pain, floaters, increased intraocular pressure
• Vitreous floaters/detachment, blurred vision, dry eye, visual disturbance
• Cataract (progression), conjunctival hyperemia

Serious (uncommon but important)

• Endophthalmitis (intraocular infection)
• Retinal detachment or tear
• Traumatic cataract from injection
• Sustained increase in intraocular pressure
• Arterial thromboembolic events (e.g. stroke, myocardial infarction) – small increased risk

Patients should seek urgent ophthalmologic review for eye pain, redness, light sensitivity, or sudden vision changes after a Lucentis injection.

Pregnancy: Systemic exposure to Lucentis after intravitreal injection is expected to be very low; however, VEGF inhibition may theoretically affect fetal vascular development, and clinical data in pregnant women are limited. Lucentis should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether Lucentis is excreted in human milk. Because systemic absorption after intravitreal injection is minimal, risk to a breastfed infant is expected to be low, but caution is advised; a physician should be consulted to weigh the benefits of treatment against any theoretical risk.

Lucentis requires careful precautions due to both the injection procedure and its pharmacologic effect:

• Endophthalmitis and retinal detachment: intravitreal injections, including Lucentis, carry a risk of endophthalmitis and retinal detachment. Strict aseptic injection technique is required, and patients must be instructed to report immediately any eye pain, increasing redness, photophobia, blurred vision, or increased floaters after the injection.
• Intraocular pressure (IOP) elevation: transient increases in IOP can occur within minutes of injection; IOP and optic nerve head perfusion should be monitored and managed appropriately.
• Arterial thromboembolic events (ATEs): a small increased risk of ATEs (such as stroke or myocardial infarction) has been observed with anti-VEGF agents including Lucentis; caution is warranted in patients with prior stroke, transient ischemic attack, or myocardial infarction.
• Administration requirements: Lucentis must be administered only by a qualified ophthalmologist under controlled aseptic conditions; it must never be self-administered.

Overdose of Lucentis is uncommon given controlled administration by a physician, but accidental higher-volume intravitreal injection or unintended systemic exposure may increase intraocular pressure or ocular adverse effects. If overdose is suspected, the patient should seek immediate medical attention or contact the treating ophthalmologist/emergency services promptly for evaluation and monitoring of intraocular pressure and visual function; no specific antidote exists.

Store Lucentis refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the vial/pre-filled syringe in the outer carton to protect from light until ready to use. Do not shake. Keep out of reach of children. Once removed from the refrigerator for use, follow the product-specific instructions for room-temperature stability before administration.

Renal impairment

No dose adjustment of Lucentis is required in patients with renal impairment, as systemic exposure is minimal.

Hepatic impairment

No specific studies have been conducted in hepatic impairment; no dose adjustment is considered necessary given minimal systemic absorption.

Elderly

No dose adjustment is required based on age alone; efficacy and safety are well established in the elderly population typically affected by wet AMD.

Pediatric population

Lucentis is approved for retinopathy of prematurity (ROP) at a lower pediatric-specific dose (0.2 mg per eye) under specialist ophthalmology care. Safety and efficacy for other pediatric ophthalmic indications have not been established.

Duration of treatment with Lucentis is individualized based on the indication and the patient's anatomical and visual response, typically assessed monthly. For wet AMD, DME, DR, and RVO-related macular edema, treatment often begins with monthly injections and may transition to an extended or as-needed (pro re nata) regimen based on disease activity, as determined by the treating ophthalmologist. For myopic CNV, treatment is often limited to as few injections as needed to achieve and maintain stable vision, commonly up to 3 initial monthly doses. Treatment duration should be regularly reassessed; ongoing benefit and safety should be reviewed at each visit.

Ranibizumab is classified as a vascular endothelial growth factor (VEGF) inhibitor, specifically an anti-VEGF-A monoclonal antibody fragment (Fab), within the broader category of ophthalmic anti-angiogenic biologic agents.

Ranibizumab is a recombinant humanized Fab fragment that binds with high affinity to all active isoforms of VEGF-A, blocking its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on vascular endothelial cells. This inhibits VEGF-A-mediated endothelial cell proliferation, neovascularization, and vascular permeability, thereby reducing abnormal blood vessel growth and fluid leakage within the retina and choroid.

C

Lucentis is approved for use in preterm infants with retinopathy of prematurity (ROP), administered at a lower pediatric-specific dose (0.2 mg per eye) by a pediatric ophthalmology specialist experienced in intravitreal injection in infants, with close monitoring for ocular and systemic adverse effects. For other pediatric retinal conditions, safety and efficacy of Lucentis have not been established, and use should occur only under specialist supervision when benefits are judged to outweigh risks.